PE20080851A1 - Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma - Google Patents

Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma

Info

Publication number
PE20080851A1
PE20080851A1 PE2007000720A PE2007000720A PE20080851A1 PE 20080851 A1 PE20080851 A1 PE 20080851A1 PE 2007000720 A PE2007000720 A PE 2007000720A PE 2007000720 A PE2007000720 A PE 2007000720A PE 20080851 A1 PE20080851 A1 PE 20080851A1
Authority
PE
Peru
Prior art keywords
methyl
indol
phenyl
propenamide
hydroxy
Prior art date
Application number
PE2007000720A
Other languages
English (en)
Spanish (es)
Inventor
Murat Acemoglu
Joginder S Bajwa
David John Parker
Joel Slade
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080851(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20080851A1 publication Critical patent/PE20080851A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2007000720A 2006-06-12 2007-06-08 Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma PE20080851A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80452706P 2006-06-12 2006-06-12
US86787806P 2006-11-30 2006-11-30

Publications (1)

Publication Number Publication Date
PE20080851A1 true PE20080851A1 (es) 2008-08-18

Family

ID=38832681

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007000720A PE20080851A1 (es) 2006-06-12 2007-06-08 Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma
PE2011002097A PE20120221A1 (es) 2006-06-12 2007-06-08 Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011002097A PE20120221A1 (es) 2006-06-12 2007-06-08 Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma

Country Status (31)

Country Link
US (2) US20090306405A1 (enExample)
EP (2) EP2032533B8 (enExample)
JP (2) JP5431926B2 (enExample)
KR (2) KR101493530B1 (enExample)
CN (4) CN103086944A (enExample)
AR (1) AR061296A1 (enExample)
AU (1) AU2007257883B2 (enExample)
BR (1) BRPI0712847A2 (enExample)
CA (1) CA2653657C (enExample)
CL (2) CL2007001691A1 (enExample)
DK (1) DK2032533T3 (enExample)
EC (1) ECSP088978A (enExample)
ES (2) ES2416286T3 (enExample)
GT (1) GT200800282A (enExample)
HR (1) HRP20130798T1 (enExample)
IL (2) IL195211A (enExample)
IN (1) IN2015DN00910A (enExample)
JO (1) JO2900B1 (enExample)
MA (1) MA30513B1 (enExample)
MX (2) MX366213B (enExample)
MY (1) MY147576A (enExample)
NO (1) NO341870B1 (enExample)
NZ (1) NZ572707A (enExample)
PE (2) PE20080851A1 (enExample)
PL (1) PL2032533T3 (enExample)
PT (1) PT2032533E (enExample)
RU (1) RU2448090C2 (enExample)
TN (1) TNSN08507A1 (enExample)
TW (1) TWI395734B (enExample)
WO (1) WO2007146718A2 (enExample)
ZA (1) ZA200809490B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000004075A1 (it) 2020-02-27 2021-08-27 Flamma Spa Processo per la preparazione di panobinostat

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB146260A (en) 1918-07-11 1921-08-11 Elektro Osmose Ag A process for preparing proteids charged with immune substances
GB8531612D0 (en) * 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AU2002237261A1 (en) 2001-01-09 2002-07-24 Novartis Pharma Gmbh Rapid method for screening compounds for in vivo activity
KR100937064B1 (ko) 2001-11-06 2010-01-15 노파르티스 아게 시클로옥시게나제-2 억제제/히스톤 데아세틸라제 억제제복합제제
MY147013A (en) * 2006-06-12 2012-10-15 Novartis Ag Process for making salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide

Also Published As

Publication number Publication date
AU2007257883A1 (en) 2007-12-21
KR101493530B1 (ko) 2015-02-13
NO341870B1 (no) 2018-02-12
KR20090015969A (ko) 2009-02-12
HK1126759A1 (en) 2009-09-11
DK2032533T3 (da) 2013-07-01
EP2032533B1 (en) 2013-04-03
GT200800282A (es) 2009-03-09
KR20140117703A (ko) 2014-10-07
PL2032533T3 (pl) 2013-08-30
RU2448090C2 (ru) 2012-04-20
US20120010418A1 (en) 2012-01-12
TW200815345A (en) 2008-04-01
JP5809223B2 (ja) 2015-11-10
AR061296A1 (es) 2008-08-20
MX2008015898A (es) 2009-01-12
HRP20130798T1 (en) 2013-09-30
HK1162029A1 (en) 2012-08-17
PT2032533E (pt) 2013-06-28
ES2553255T3 (es) 2015-12-07
JO2900B1 (en) 2015-09-15
IL195211A0 (en) 2009-08-03
WO2007146718A2 (en) 2007-12-21
US20090306405A1 (en) 2009-12-10
IL233836A0 (en) 2014-09-30
EP2032533B8 (en) 2013-12-11
CN103086944A (zh) 2013-05-08
WO2007146718A3 (en) 2008-06-19
CN102174008A (zh) 2011-09-07
CA2653657A1 (en) 2007-12-21
MA30513B1 (fr) 2009-06-01
ZA200809490B (en) 2009-10-28
CN102167678B (zh) 2013-08-28
CN101466674A (zh) 2009-06-24
ES2416286T3 (es) 2013-07-31
TNSN08507A1 (en) 2010-04-14
NO20090137L (no) 2009-03-03
CN102167678A (zh) 2011-08-31
US8536346B2 (en) 2013-09-17
IN2015DN00910A (enExample) 2015-07-10
EP2032533A2 (en) 2009-03-11
AU2007257883B2 (en) 2011-09-29
CA2653657C (en) 2015-10-27
NZ572707A (en) 2011-12-22
EP2394991A1 (en) 2011-12-14
CL2010000973A1 (es) 2011-07-01
IL233836A (en) 2017-05-29
PE20120221A1 (es) 2012-03-21
JP2009540008A (ja) 2009-11-19
MY147576A (en) 2012-12-31
TWI395734B (zh) 2013-05-11
IL195211A (en) 2014-08-31
ECSP088978A (es) 2009-01-30
JP5431926B2 (ja) 2014-03-05
RU2008151726A (ru) 2010-07-20
JP2014058532A (ja) 2014-04-03
BRPI0712847A2 (pt) 2012-08-07
EP2394991B1 (en) 2015-09-23
MX366213B (es) 2019-07-01
CL2007001691A1 (es) 2008-05-16
KR101540194B1 (ko) 2015-07-28

Similar Documents

Publication Publication Date Title
ES2665461T3 (es) Moduladores del receptor esfingosina 1-fosfato y métodos de síntesis quiral
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
ES2525566T3 (es) Nuevo derivado de hidroxamato, método para producirlo y composición farmacéutica que lo contiene
CL2020002290A1 (es) Compuestos de aminoácidos y métodos de uso.
CO6140053A2 (es) Proceso para fabricar 2-amino-5-halobenzamidas 3-sustituidas
NZ579833A (en) 7-substituted indole mcl-1 inhibitors
PE20140879A1 (es) Antagonistas del receptor de acido lisofosfatidico para el tratamiento de fibrosis
AR047812A1 (es) Compuestos de tetrazol y su uso como antagonistas del receptor de glutamato metabotropico
RU2010145171A (ru) Аналоги галихондрина в
RU2013116924A (ru) N1/n2-лактамные ингибиторы ацетил-коа-карбоксилаз
NI200800227A (es) Acidos 1,3-dioxano carboxilicos
TNSN07014A1 (en) New heterocyclic carboxylic acid amide derivatives
ES2570934T3 (es) Sales de N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-il)etil]amino]metil]fenil]-2E-2-propenamida
CY1115623T1 (el) Μεθοδος για την συνθεση 7,8-διμεθοξυ-1,3-διϋδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη αυτης στη συνθεση της ιβαμπραδινης καθως επισης αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
PE20121805A1 (es) Derivados de 6-oxo-1,6-dihidropiridazin-4-carboxamida n-sustituidas con anilino-(bencil o piridinilmetil)-carbamoilo como antagonistas del receptor de bradiquinina 1 (b1)
MX2008015899A (es) Procedimiento para hacer sales de n-hidroxi-3-[4-[[[2-(2-metil-1h- indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida.
PE20040907A1 (es) Derivados de anilinopirazol
EA201270099A1 (ru) Транс-4-[[(5s)-5-[[[3,5-бис(трифторметил)фенил]метил](2-метил-2h-тетразол-5-ил)амино]-2,3,4,5-тетрагидро-7,9-диметил-1h-1-бензазепин-1-ил]метил]циклогексанкарбоновая кислота
PE20120732A1 (es) Agonistas del receptor de esfingosina-1-fosfato
PE20121052A1 (es) Composicion de sal no apelmazante y procedimiento de preparacion de la misma
RU2010147938A (ru) Способ получения промежуточных соединений нафталин-2-ид-пиразол-3-она, используемых в синтезе ингибиторов сигма рецептора
PE20080851A1 (es) Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma
ES394917A1 (es) Procedimiento para la preparacion de nuevos 1-fenoxi-2-hi- droxi - 3 - alcohilaminopropanos racemicos u opticamente ac-tivos.
PE20131219A1 (es) Metodo para la preparacion de acido montelukast en un medio liquido ionico
AR059546A1 (es) Derivados de cromen -2-ona utiles como inhibidores de recaptacion del neurotransmisor de monoamina

Legal Events

Date Code Title Description
FG Grant, registration